Bristol Myers Squibb (CELG-RI) Total Liabilities (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Total Liabilities of $65.3 billion for Q2 2026, down 15.38% year-over-year from $77.2 billion in Q2 2025, and down 1.6% quarter-over-quarter from $66.4 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) Total Liabilities (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Total Liabilities for 18 consecutive years, with $65.3 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Total Liabilities fell 15.38% year-over-year to $65.3 billion; the TTM figure through Jun 2026 stood at $65.3 billion (down 15.38% YoY), while the FY2025 annual figure was $71.5 billion, down 6.14% from the prior year.
- Total Liabilities fell to $65.3 billion in Q2 2026 per CELG-RI's latest filing, from $66.4 billion in the prior quarter.
- Across five years, Total Liabilities topped out at $82.5 billion in Q1 2024 and bottomed at $61.5 billion in Q2 2023.
- Historically, Total Liabilities has averaged $70.5 billion across 5 years, with a median of $69.5 billion in 2022.
- Annual changes were most pronounced in 2024 — Total Liabilities soared 32.19% — and 2026, when it decreased 15.38%.
- Bristol Myers Squibb's Total Liabilities stood at $65.7 billion in 2022, then decreased by 0.04% to $65.7 billion in 2023, then grew by 16.05% to $76.2 billion in 2024, then retreated by 6.14% to $71.5 billion in 2025, then slipped by 8.69% to $65.3 billion in 2026.
- Business Quant data shows CELG-RI's Total Liabilities at $65.3 billion in Q2 2026, $66.4 billion in Q1 2026, and $71.5 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 651.33 Bn | 630.58 Bn | 17.26 Bn | 116.09 Bn |
| 2 | AbbVie | 469.67 Bn | 463.10 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 374.13 Bn | 366.99 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 302.76 Bn | 295.07 Bn | 11.24 Bn | 80.09 Bn |
| 5 | Astrazeneca | 257.15 Bn | 252.25 Bn | 12.86 Bn | 65.46 Bn |
| 6 | Amgen | 236.76 Bn | 222.77 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 182.54 Bn | 179.36 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 159.57 Bn | 147.87 Bn | 10.94 Bn | 115.64 Bn |
| 9 | Gsk | 105.99 Bn | 101.83 Bn | 8.24 Bn | -59.79 Bn |
| 10 | Bristol Myers Squibb | 208.28 Mn | -10.86 Bn | 9.25 Bn | 65.32 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 65.32 Bn |
| Mar 31, 2026 | 66.37 Bn |
| Dec 31, 2025 | 71.53 Bn |
| Sep 30, 2025 | 78.29 Bn |
| Jun 30, 2025 | 77.19 Bn |
| Mar 31, 2025 | 74.98 Bn |
| Dec 31, 2024 | 76.22 Bn |
| Sep 30, 2024 | 76.47 Bn |
| Jun 30, 2024 | 77.58 Bn |
| Mar 31, 2024 | 82.48 Bn |
| Dec 31, 2023 | 65.67 Bn |
| Sep 30, 2023 | 62.20 Bn |
| Jun 30, 2023 | 61.46 Bn |
| Mar 31, 2023 | 62.40 Bn |
| Dec 31, 2022 | 65.70 Bn |
| Sep 30, 2022 | 65.46 Bn |
| Jun 30, 2022 | 67.70 Bn |
| Mar 31, 2022 | 71.39 Bn |
| Dec 31, 2021 | 73.31 Bn |
| Sep 30, 2021 | 73.61 Bn |